The US Food and Drug Administration (FDA) has granted fast track designation for the development of Bracco Imaging's molecular imaging ultrasound contrast agent, BR55, to identify active bowel ...
BR55 injection, an investigational contrast agent for ultrasounds ... Chief Medical and Regulatory Officer, Bracco Imaging Group. “This Fast Track designation supports our goal to get BR55 ...
The company is currently preparing for Phase III trials to further assess the efficacy and safety of the agent in identifying active inflammation in individuals with Crohn's disease. Credit ...